Grail Inc expected to post a loss of $2.65 a share - Earnings Preview
Grail Inc expected to post a loss of $2.65 a share - Earnings Preview
Grail Inc GRAL.OQ GRAL.O is expected to show a rise in quarterly revenue when it reports results on August 5 for the period ending June 30 2026
The Menlo Park California-based company is expected to report a 20.3% increase in revenue to $42.76 million from $35.54 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Grail Inc is for a loss of $2.65 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Grail Inc is $63.07, about 10.3% below its last closing price of $70.27
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -2.81 | -2.76 | -2.29 | Beat | 17.1 |
Dec. 31 2026 | -2.57 | -2.71 | -2.44 | Beat | 9.8 |
Sep. 30 2025 | -3.49 | -3.52 | -2.46 | Beat | 30.1 |
Jun. 30 2025 | -3.55 | -3.57 | -3.18 | Beat | 10.9 |
Mar. 31 2025 | -4.05 | -4.09 | -3.10 | Beat | 24.2 |
Dec. 31 2024 | -5.10 | -4.97 | -2.91 | Beat | 41.5 |
-3.35 | |||||
-51.06 |
This summary was machine generated August 3 at 23:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Grail
See all newsGrail rises as TD Cowen more than doubles PT on FDA, Medicare optimism
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
U.S. RESEARCH ROUNDUP-Chevron, Mobility Global, Tesla
Street View: Grail cancer test's progress boosts prospects for multi-cancer detection market
NASDAQ RESUMED AT 07:05 AM